Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase

Journal of Medicinal Chemistry
Diane E GingrichBruce D Dorsey

Abstract

Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancer, supported by considerable favorable preclinical and clinical activities over the past several years and culminating in the recent FDA approval of the ALK inhibitor crizotinib. Through a series of targeted modifications on an ALK inhibitor diaminopyrimidine scaffold, our research group has driven improvements in ALK potency, kinase selectivity, and overall pharmaceutical properties. Optimization of this scaffold has led to the identification of a potent and efficacious inhibitor of ALK, 25b. A striking feature of 25b over previously described ALK inhibitors is its >600-fold selectivity over insulin receptor (IR), a closely related kinase family member. Most importantly, 25b exhibited dose proportional escalation in rat compared to compound 3 which suffered dose limiting absorption preventing further advancement. Compound 25b exhibited significant in vivo antitumor efficacy when dosed orally in an ALK-positive ALCL tumor xenograft model in SCID mice, warranting further assessment in advanced preclinical models.

References

Oct 1, 1988·Trends in Biochemical Sciences·J Espinal
Apr 5, 1996·Analytical Biochemistry·T S AngelesC A Dionne
Aug 3, 2002·The Journal of Organic Chemistry·George A Kraus, Prabir K Choudhury
Dec 26, 2003·The New England Journal of Medicine·Alan R Saltiel
Dec 23, 2006·Proceedings of the National Academy of Sciences of the United States of America·Anna V GalkinMarkus Warmuth
Dec 22, 2007·Nature Reviews. Cancer·Roberto ChiarleGiorgio Inghirami
Aug 20, 2008·Journal of Medicinal Chemistry·Arup K GhoseJohn P Mallamo
Oct 17, 2008·Nature·Charis Eng
Oct 17, 2008·Nature·Isabelle Janoueix-LeroseyOlivier Delattre
Oct 17, 2008·Nature·Yuyan ChenSeishi Ogawa
Mar 12, 2009·Expert Review of Anticancer Therapy·Thomas R WebbStephan W Morris
Sep 10, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yael P MosséJohn M Maris
Mar 20, 2010·Clinical Pharmacology and Therapeutics·F StegmeierM Dorsch
Jul 17, 2010·The Biochemical Journal·Christian C LeeGlen Spraggon
Oct 1, 2010·Nature·J S de Bono, Alan Ashworth
Oct 22, 2010·Expert Opinion on Therapeutic Patents·Karen L Milkiewicz, Gregory R Ott
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Nov 26, 2010·The Mount Sinai Journal of Medicine, New York·Stacey J Baker, E Premkumar Reddy
Feb 1, 2011·The Lancet Oncology·William Pao, Nicolas Girard
Feb 4, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alice T Shaw, Benjamin Solomon
Mar 19, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN Alzheimer's Association
Apr 9, 2011·Molecular Cancer Therapeutics·Enrique GrandeEdurne Arriola
Apr 20, 2011·Proceedings of the National Academy of Sciences of the United States of America·Ryohei KatayamaAlice T Shaw
May 14, 2011·Lancet·Peter GoldstrawFrances A Shepherd
Dec 9, 2010·ACS Medicinal Chemistry Letters·Gregory R OttBruce D Dorsey

❮ Previous
Next ❯

Citations

Oct 17, 2013·Archives of Pharmacal Research·Jeong In YunHyoung Rae Kim
Jun 19, 2013·Best Practice & Research. Clinical Haematology·Catherine Lai, Kieron Dunleavy
Dec 4, 2012·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Robert Roskoski
Mar 10, 2016·The Veterinary Quarterly·M Zandvliet
Jan 31, 2014·Expert Opinion on Therapeutic Patents·Eugen F MesarosBruce D Dorsey
Jun 9, 2017·The Journal of Physical Chemistry. B·Kaori FujiiYoshifumi Kimura
Mar 10, 2019·Journal of Labelled Compounds & Radiopharmaceuticals·Simone ThumBernhard Wünsch
May 1, 2021·ChemPlusChem·Andrej JancarikAndre Gourdon
Dec 29, 2020·Journal of Medicinal Chemistry·Muhammad FaisalSo Ha Lee
Aug 17, 2019·Journal of Medicinal Chemistry·Xiaotian KongTingjun Hou
Jan 10, 2013·ACS Medicinal Chemistry Letters·Bryan K ChanZachary K Sweeney
Aug 8, 2019·Journal of the American Chemical Society·Ying XiaGuangbin Dong

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.